Amylin Analog Therapeutics Market Size, Share, Trend, Forecast Report 2026 to 2035

What is Amylin Analog Therapeutics Market Size?

Amylin Analog Therapeutics Market is likely to witness the growth at a 28.5% CAGR during the forecast period for 2026 to 2035.

Amylin Analog Therapeutics Market Size, Share & Trends Analysis Distribution by Therapeutic Class / Product Architecture (Amylin Monotherapy, Selective Amylin Receptor Agonists, Dual Amylin & Calcitonin Receptor Agonists, GLP-1–Amylin Combination Therapy, Fixed-Dose (Multi-Molecule) Combinations, Unimolecular GLP-1 / Amylin Co-Agonists, Amylin–Insulin Combination Therapy), by Route of Administration & Formulation (Injectable, Oral, Oral Peptide, Oral Small Molecule), by Indication / Patient Population (Chronic Weight Management, Obesity / Overweight with Type 2 Diabetes, Insulin-Treated Diabetes) and Segment Forecasts, 2026 to 2035

Amylin is a naturally occurring hormone involved in appetite regulation, gastric emptying, and post-meal glucose control. Amylin analogs are designed to reproduce these effects and may therefore offer benefits across both weight management and glycemic control. This has made amylin-based therapies particularly relevant in the treatment of obesity and type 2 diabetes, where controlling body weight and blood glucose levels remains a major clinical challenge. Companies are also exploring amylin therapies as standalone treatments and in combination with established metabolic medicines, including GLP-1 therapies and insulin, with the aim of improving satiety, supporting greater weight reduction, and achieving better overall metabolic control. The increasing prevalence of obesity and diabetes, together with rising demand for effective pharmacological weight-management options, is creating a favourable environment for the development of amylin-based treatments. The amylin analog therapeutics market is attracting growing interest as pharmaceutical companies look for new and more effective approaches to treating obesity, overweight, and metabolic disorders. 

Innovation in how these drugs are designed and delivered is shaping the amylin analog therapeutics market

Developers are working on longer-lasting amylin receptor agonists, better peptide formulas, and combination therapies that can provide stronger and longer-lasting effects while staying safe and tolerable. New amylin analogs are being made to be more stable, last longer in the body, and possibly require fewer doses. Another key area is combining GLP-1 and amylin therapies, using fixed-dose combinations or single molecules that target several metabolic pathways at once. Improvements in peptide engineering, new formulation methods, and sustained-release delivery systems are helping companies overcome some of the challenges of traditional peptide drugs. However, there are still hurdles, such as complex manufacturing, keeping the drugs stable, cold storage needs, injections, making sure patients stick to treatment, and the need for thorough long-term testing. Competition from existing obesity and diabetes treatments may also affect how new amylin-based products are positioned and adopted in the market.

The long-term outlook for the amylin analog therapeutics market looks positive as healthcare systems deal with rising rates of obesity, type 2 diabetes, and related conditions. Ongoing investment in new peptide therapies is expected to lead to treatments that can be taken less often, are more convenient, and offer wider benefits for metabolism. Injectable therapies will likely stay important, but research into oral delivery and other new methods could make these treatments available to more people. Combination therapies that target amylin, GLP-1, insulin, and other metabolic pathways at the same time may also open up new possibilities for unique products. As studies continue to show that targeting multiple pathways can help people lose weight and control blood sugar over the long term, amylin analogs are set to play a bigger role in treating obesity and metabolic diseases.

Competitive Landscape

Which are the Leading Players in the Amylin Analog Therapeutics Market ?

• Novo Nordisk A/S
• Eli Lilly and Company
• Zealand Pharma A/S
• F. Hoffmann-La Roche Ltd
• AstraZeneca plc
• AbbVie Inc.
• Gubra A/S
• Pfizer Inc.
• Structure Therapeutics Inc.
• Viking Therapeutics Inc.
• Verdiva Bio Limited
• Adocia S.A.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Innovent Biologics, Inc.
• Hanmi Pharmaceutical Co., Ltd.
• Kailera Therapeutics, Inc.
• Altimmune, Inc.

Market Dynamics

Driver

Rising Demand for Effective and Durable Pharmacological Weight-Management Therapies

The growing global burden of obesity and overweight is creating strong demand for new pharmacological treatments that can deliver meaningful and sustained weight reduction. While GLP-1-based therapies have transformed the obesity and diabetes treatment landscape, there is increasing interest in additional mechanisms that can improve appetite control, satiety, and metabolic outcomes. Amylin analogs are gaining attention because amylin naturally contributes to appetite regulation, delayed gastric emptying, and post-meal glucose control. This is encouraging pharmaceutical companies to develop selective amylin receptor agonists, dual amylin and calcitonin receptor agonists, and other next-generation therapies. The opportunity is particularly strong in chronic weight management and in patients with obesity or overweight alongside type 2 diabetes, where both weight reduction and improved metabolic control are important treatment goals.

Restraint / Challenge

Complex Peptide Development, Manufacturing Requirements, and Long-Term Safety Considerations

Even though amylin analog therapies show promise, they face several challenges in development and commercialization. Many of these drugs are peptides, which makes them harder to manufacture, store, and deliver than traditional small-molecule medicines. Since most are given by injection, some patients may be put off if they prefer pills or less frequent dosing. Companies also need to prove that these treatments work well, are safe, and can be used long-term, since obesity and diabetes medicines are often taken for years. Other issues include side effects like stomach problems, making sure patients stick to their treatment, high production costs, and competition from existing GLP-1 drugs. Creating stable and easy-to-use versions of these medicines is still a major challenge for the industry.

GLP-1–Amylin Combination Therapy Segment is Expected to Drive the Amylin Analog Therapeutics Market

The GLP-1 and amylin combination therapy segment is expected to be a key growth area in the amylin analog therapeutics market. By combining the effects of amylin and GLP-1, these treatments can target several factors involved in appetite, fullness, blood sugar, and weight control. Companies are testing both fixed-dose combinations and single molecules that act on both GLP-1 and amylin pathways, hoping for better and longer-lasting results. Interest in these multi-hormone approaches is growing, leading to more investment. If these therapies show real benefits in weight loss, blood sugar control, safety, and ease of use, they could become a strong competitor in the obesity treatment market.

Chronic Weight Management Segment is Expected to Drive the Amylin Analog Therapeutics Market

The chronic weight management segment is expected to represent a major growth opportunity as obesity is increasingly recognised as a long-term metabolic disease requiring sustained treatment. Patients and healthcare providers are seeking therapies that can deliver substantial and durable weight reduction while supporting long-term treatment adherence. Amylin analogs may offer a complementary mechanism to existing weight-management medicines by influencing appetite, satiety, gastric emptying, and food intake. Development activity in selective amylin receptor agonists, dual amylin and calcitonin receptor agonists, and GLP-1/amylin co-agonists is expanding the potential role of amylin-based therapies in long-term obesity management. Growing demand for pharmacological treatment among individuals who are unable to achieve sufficient weight reduction through lifestyle interventions alone is expected to further support this segment.

Why North America Leads the Amylin Analog Therapeutics Market?

North America is expected to maintain a leading position in the Amylin Analog Therapeutics Market, supported by the high prevalence of obesity and type 2 diabetes, strong demand for advanced metabolic therapies, substantial pharmaceutical R&D investment, and the presence of major biotechnology and pharmaceutical companies. The United States, in particular, has a well-developed clinical research ecosystem and a strong commercial market for obesity and diabetes medicines. Increasing healthcare awareness, growing adoption of prescription weight-management therapies, and continued investment in next-generation peptide and multi-hormone treatments are supporting regional market development. The presence of companies developing innovative amylin-based and combination therapies further strengthens North America's position. 

At the same time, Asia Pacific is expected to witness significant growth during the forecast period. Rising rates of obesity, diabetes, and other metabolic disorders, expanding healthcare infrastructure, increasing awareness of medical weight management, and growing pharmaceutical investment are creating new opportunities across the region. Countries such as China, Japan, South Korea, India, and Australia are strengthening their capabilities in pharmaceutical research, clinical development, and advanced drug manufacturing. As access to obesity and diabetes treatments improves and demand for innovative metabolic therapies increases, Asia Pacific is expected to become an increasingly important market for amylin analog therapeutics.

Key Developments-

• In January 2025, Novo Nordisk A/S continued advancing its next-generation obesity and metabolic disease pipeline, with ongoing development of amylin-based and combination approaches designed to provide greater weight reduction and improved metabolic control. The company's broader investment in multi-hormonal therapies strengthens its position in the emerging amylin therapeutics landscape.

• In March 2025, Zealand Pharma A/S continued advancing its peptide-based obesity pipeline, including amylin-related and multi-pathway approaches. Its focus on novel peptide therapeutics positions the company as an important emerging participant in next-generation weight-management treatments.

Amylin Analog Therapeutics Market  Report Scope: